$VVOS

Vivos Therapeutics, Inc. (VVOS): Entry into a Material Definitive Agreement

Vivos Therapeutics, Inc. (VVOS) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01 Entry into a Material Definitive Agreement. As previously reported, Vivos Therapeutics, Inc. (the “Company”) previously sold and issued to Streeterville Capital, LLC, a Utah limited liability company (“Streeterville”), a Secured Promissory Note with an original issuance

Original reporting
Published Sep 4, 2026, 10:26 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 8, 2026, 10:03 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefCorporate actions
Primary signal
$VVOS
Bearish
medium confidence
Mentioned
$VVOS
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$VVOSBearishMed
01

Why it matters

The dilution could trigger a price decline as existing shareholders face ownership reduction, but the debt reduction may strengthen the balance sheet.

02

Market read

Primary micro‑cap equity dilution event with material impact on VVOS price and potential sector ripple effects.

03

What to watch

The issuance is tied to settlement of debt, potentially improving balance‑sheet health.

Relevance 6/10Novelty 8/10Timing: post filing Sep 4 2026

Background

Vivos Therapeutics filed an 8‑K detailing exchange agreements with Streeterville Capital that convert $2.86 M of debt into common stock, increasing share count by over 50%.

Company-level read

Ticker impact

$VVOSBearishMedium confidence
Context

The 8‑K reports a material equity issuance of up to 11.4 M shares, diluting existing shareholders by ~52% and increasing shares outstanding to 33.6 M.

Expected impact

Potential short‑term downside of 5‑10% as market absorbs the dilution.

Evidence & confidence

Large share count increase relative to current float, with restrictive ownership limits, suggests selling pressure.

Market effects

Dilution may affect peer biotech valuations as investors reassess financing structures.

Primarily U.S. micro‑cap market; limited broader regional effect.

Low global relevance beyond niche biotech investors.

Counterpoint

If the capital raised funds promising pipeline milestones, the long‑term upside could outweigh short‑term dilution pain.

Key entities

  • Vivos Therapeutics, Inc.

    Biotech firm issuing new shares to settle debt.

  • Streeterville Capital, LLC

    Creditor receiving equity in exchange for debt.

Related articles

$VVOSMed

Vivos’ Vida® Appliance Shows Statistically Significant Improvement in Insomnia Severity in 100% of Study Participants

Vivos Therapeutics (NASDAQ: VVOS) reported single-site clinical study results for its FDA-cleared Vida oral appliance in 37 adults with moderate-to-severe insomnia. All participants improved at least one Insomnia Severity Index category; average ISI fell ~65% and all ended as no clinically significant or subthreshold insomnia (p~1e-7). Vivos cites potential market expansion beyond OSA/COMISA.

$VVOSMed

Vivos, SPCVA Form AIM Florida To Expand Sleep Apnea And Insomnia Care For CVD Patients

Vivos Therapeutics (VVOS) said it will collaborate with South Palm Cardiovascular Associates (SPCVA) to form AIM Florida, LLC, a physician-aligned management services organization to expand integrated diagnosis and treatment for obstructive sleep apnea and insomnia in cardiovascular disease patients. Vivos expects to hold at least 80% of AIM Florida. The initial focus is Palm Beach County.

$SNOWHighAI 9/10

Snowflake Upsizes Convertible Note Offering to $3.75 Billion - Snowflake (NYSE:SNOW)

Snowflake (NYSE:SNOW) upsized its convertible note offering to $3.75B, including $2B due 2029 and $1.75B due 2031, with potential for $550M more. Notes have initial conversion prices at 52.5% and 47.5% premiums to recent stock price. Company plans to use proceeds to repurchase existing notes and for general corporate purposes. Shares were down 0.57% at $326.24 at the time of publication.

$NVDAHighAI 8/10

Nvidia's next 'holy grail' is physical AI: Dan Ives

Analyst Dan Ives predicts Nvidia's (NVDA) financial growth will be driven by physical AI, including robotics and automation, in 2025. The company announced a $150 billion stock buyback plan, the largest in history, bringing its total authorization to $235 billion. Nvidia's shares have historically gained 24% in the 12 months following large buyback plans, according to FedWatch Advisors founder Ben Emons.

$BAHighAI 8/10

NASA pays Boeing $359m to get Starliner flying, eyes crew return by 2028

NASA will pay Boeing $359m to fix Starliner's thrusters and certify ULA's Vulcan rocket for crewed flights, with plans to resume astronaut missions by 2028. The funds cover two additional ISS flights, bringing NASA's total Starliner missions to six. Boeing has incurred over $2bn in losses on the Starliner program. NASA aims to use Starliner for crew transport to private space stations post-ISS.

$NVDAHighAI 8/10

Nvidia readies biggest-ever share buyback plan

Nvidia authorized a $150 billion share buyback, the largest ever, boosting its total to $235 billion. Shares rose 2% on the news. The company expects to deploy the buyback through fiscal 2028, signaling confidence in AI demand. Nvidia's stock is up 20% this year, trailing peers like AMD and Intel. CEO Jensen Huang cited strong cash generation for the buyback and investments. The company forecast 70% revenue growth for fiscal 2028.